Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers - Switzerland
doi 10.3390/cancers11111642
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

MDPI AG

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy